Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Abeona Therapeutics Inc.NASDAQ: ABEO

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income grows, but more slowly than its trailing trend

Q1 FY2026 net income of $17.08M (cash outflow) rose 41.9% year over year, behind the +249.7% change in trailing-twelve-month net income. Sequentially, it fell 16.5% from the prior quarter.

Context

  • Net income amounted to 1223.1% of revenue in FY2025.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$60.34M (-184.8%) for the fiscal year ending Dec 2026, a slowdown from the +211.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$17.08M-16.5% QoQ
Last fiscal yearDec 2025
$71.18M+211.7% YoY
LTMMar 2026
$66.14M+249.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.9%-112.3%-154.3 pp
1 year+211.7%-184.8%-396.5 pp
3-year CAGR—-64.2%—
5-year CAGR+10.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
71.18M USD
Year-over-year change
+211.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 net income of $66.14M is the 7th largest of the 10 companies compared; the peer median is $78.15M.
  • Its year-over-year change of +249.7% is the highest of 10, against a peer median of -6.4%.
  • Net income amounts to 454.9% of revenue for ABEO, versus a peer median of 266.9%.
ABEO Competitors Peer median
Net Income for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$116.64M +37.7%+37.1%319.6%
HUMAHumacyte, Inc.LTM Mar 2026$97.59M +25.7%+50.6%4840.8%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$83.01M -21.5%-9.9%36891.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$78.67M +15.4%—173.5%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$78.15M +141.3%-19.7%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$75.32M -6.4%-12.0%266.9%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$66.14M +249.7%—454.9%
SGMTSagimet Biosciences Inc.LTM Mar 2026$43.51M -23.8%+18.7%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M -35.9%+2396.3%10.7%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$6.38M -84.0%-59.6%9.0%
Peer median (excluding ABEO) $78.15M-6.4%+4.4%266.9%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
Deferred Income Tax00000
Stock-Based Compensation8.92M3.05M4.77M6.63M10.78M
Change in Working Capital(18.26M)(5.89M)(1.79M)(4.38M)(5.39M)
Accounts Receivables(3M)2.81M(2.04M)792K(5.06M)
Inventory0000(5.49M)
Accounts Payables(15.59M)(9.11M)2.04M(3.49M)6.54M
Other Working Capital324K404K(3.83M)(1.68M)(1.37M)
Other Non-Cash Items24.15M(5.52M)11M2.57M(156.46M)
Operating Cash Flow(65.67M)(43.48M)(37.01M)(56.02M)(76.33M)
Capital Expenditures(4.15M)(130K)(331K)(2.45M)(7.98M)
Acquisitions (Net)00000
Purchases of Investments(20.16M)(78.21M)(51.64M)(157.01M)(206.63M)
Sales of Investments90.38M52.64M51.97M120.2M167.27M
Other Investing Activities01.73M204K18K152.37M
Investing Cash Flow66.06M(23.96M)208K(39.24M)105.03M
Debt Repayment00020M0
Common Stock Issued24.03M46.96M37.39M85.63M26.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities831K(5K)(332K)(1.49M)(37K)
Financing Cash Flow24.86M43.17M37.06M104.14M26.04M
Effect of Forex Changes00000
Net Change in Cash25.26M(24.27M)256K8.88M54.74M
Free Cash Flow(69.82M)(43.61M)(37.34M)(58.46M)(84.3M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.